Global microRNA profiles in cervical squamous cell carcinoma depend on Drosha expression levels

Prognoses in cases of uterine cervical squamous cell carcinoma treated with radiotherapy were investigated in association with immunohistochemical expression of an angiogenic factor, thymidine phosphorylase (TP). Forty-six cases of uterine cervical squamous cell carcinoma mainly treated with radiotherapy during 1992–2001 at our clinic were studied. All were diagnosed as stages IIB to IVA. Paraffin-embedded biopsy specimens excised before radiotherapy were stained immunohistochemically using anti-TP monoclonal antibody. The extent of staining in both tumor and interstitial cells was graded as (−), (±), (+), and (2+). Specimens with TP expression levels of (2+) and (+) were regarded as positively stained and those with TP expression levels of (±) and (−) as negatively stained. The efficacy of radiotherapy in both groups was analyzed by the Kaplan–Meier method. With tumor cells, 5-year survival rates for the positive (n = 38) and negative (n = 8) staining groups were 73.9% and 42.9%, respectively; the rate being significantly higher for the TP-positive group (log rank, P = 0.0096). Contrarily, with staining for interstitial cells, the 5-year survival rates for the positive (n = 20) and negative (n = 26) staining groups were 74.1% and 64.6%, respectively, with no significant difference (log rank, P = 0.406). The efficacy of radiotherapy in the group with positive staining of tumor cells was significantly better than in the negative staining group. Immunohistochemical expression of TP in tumor cells is suggested as a useful prognostic factor for uterine cervical squamous cell carcinomas treated with radiotherapy. Choosing therapy for individual cases by referring to factors including TP expression should contribute to an improved prognosis.

Download Full-text

Correlation between reticulum ribosome-binding protein 1 (RRBP1) overexpression and prognosis in cervical squamous cell carcinoma

10.21203/rs.3.rs-17769/v1 ◽

2020 ◽

Author(s):

Jiaqi Zhu ◽

Ruixue Zhao ◽

Wei Xu ◽

Jing Ma ◽

Xin Ning ◽

...

Keyword(s):

Squamous Cell Carcinoma ◽

Endoplasmic Reticulum ◽

Lymph Node ◽

Lymph Node Metastasis ◽

Cell Carcinoma ◽

Squamous Cell ◽

Binding Protein ◽

Cervical Squamous Cell Carcinoma ◽

Expression Levels ◽

Node Metastasis

Abstract Purpose: The aim of this study was to investigate the relationship between endoplasmic reticulum ribosomal binding protein 1 (RRBP1) expression in cervical squamous cell carcinoma tissues and its poor prognosis. RRBP1 is a nascent transporter on the rough endoplasmic reticulum. Its function is to regulate the transport and secretion of proteins in cells, and to relieve endoplasmic reticulum (ER) stress, thereby promoting tumor cell proliferation.Methods: The expression levels of RRBP1 in 96 cervical squamous cell carcinoma tissues were detected by immunohistochemistry. Western blot and qRT-PCR were used to compare the expression levels of RRBP1 in cervical squamous cell carcinoma tissues and normal cervical tissues. Then the chi-square test was used to analyze the results of immunohistochemistry. Finally, the Kaplan-Meier method was used to analyze the results by log-rank test and Cox regression (proportional risk model).Result: The overexpression of RRBP1 in cervical squamous cell carcinoma tissues was related to FIGO stage (P=0.030), tissue differentiation (P=0.047), lymph node metastasis (P=0.031), and was not related to the patient age (P=0.667). Univariate survival analysis showed that the prognosis was associated to the expression level of RRBP1 (P=0.045) and lymph node metastasis (P=0.001). Analysis of multi-factor survival cox model proved that RRBP1 was an independent prognostic factor. Conclusion: RRBP1 was overexpressed in cervical squamous cell carcinoma tissues, indicating that RRBP1 may be a new tumor marker for early diagnosis, treatment and prognosis of cervical squamous cell carcinoma, and it will provide help for individualized treatment and prognosis of cervical squamous cell carcinoma in the future.

Download Full-text

LncRNA MCM3AP-AS1 inhibits cell proliferation in cervical squamous cell carcinoma by down-regulating miRNA-93

Bioscience Reports ◽

10.1042/bsr20193794 ◽

2020 ◽

Vol 40 (2) ◽

Cited By ~ 1

Author(s):

Liu Lan ◽

Zhishan Liang ◽

Yingxi Zhao ◽

Yuzhen Mo

Keyword(s):

Cell Proliferation ◽

Squamous Cell Carcinoma ◽

Cell Carcinoma ◽

Squamous Cell ◽

Cervical Squamous Cell Carcinoma ◽

Down Regulation ◽

Expression Levels ◽

Methylation Specific Pcr ◽

Specific Pcr ◽

Mirna 93

Abstract Background: MCM3AP antisense RNA 1 (MCM3AP-AS1) is characterized as an oncogenic lncRNA in hepatocellular carcinoma and glioblastoma. We analyzed TCGA dataset and observed the down-regulation of MCM3AP-AS1 in cervical squamous cell carcinoma (CSCC). The present study was therefore performed to investigate the role of MCM3AP-AS1 in CSCC. Methods: A total of 64 female patients with CSCC (38–68 years old; mean age: 53.1 ± 6.5 years old) were enrolled in the present study. RT-qPCR was performed to evaluate gene expression. Methylation specific PCR (MSP) was performed to assess the methylation of miR-93 gene after the overexpression and silencing of MCM3AP-AS1. Cell transfections were performed to investigate the interactions between MCM3AP-AS1 and miR-93. Cell proliferation was assessed by CCK-8 assay. Results: The results showed that MCM3AP-AS1 was down-regulated in CSCC and predicted poor survival. The expression levels of MCM3AP-AS1 were inversely correlated with the expression levels of miR-93. Overexpression of MCM3AP-AS1 led to down-regulation of miR-93, while silencing of MCM3AP-AS1 played an opposite role in CSCC cells. Methylation-specific PCR revealed that MCM3AP-AS1 could positively regulate the methylation of miR-93 gene. Cell proliferation analysis showed that overexpression of MCM3AP-AS1 led to reduced proliferation rate of CSCC cells. Silencing of MCM3AP-AS1 played an opposite role and overexpression of miR-93 reduced the effects of overexpressing MCM3AP-AS1. Conclusions: Therefore, MCM3AP-AS1 may inhibit cell proliferation in CSCC by down-regulating miRNA-93.

Download Full-text

Exploration of potential therapeutic and prognostic value of CXC chemokines in cervical squamous cell carcinoma and endocervical adenocarcinoma based on bioinformatics analysis

Mathematical Biosciences and Engineering ◽

10.3934/mbe.2021407 ◽

2021 ◽

Vol 18 (6) ◽

pp. 8201-8222

Author(s):

Caiyun Wu ◽

◽

Cong Ma ◽

Jing Yuan ◽

Pei Zhou ◽

...

Keyword(s):

Cervical Cancer ◽

Squamous Cell Carcinoma ◽

T Cells ◽

Cell Carcinoma ◽

Squamous Cell ◽

Strong Correlation ◽

Prognostic Value ◽

Cervical Squamous Cell Carcinoma ◽

Expression Levels ◽

Endocervical Adenocarcinoma

<abstract> <p>Cervical cancer, as the second most common female malignancy, brings a great health burden to women worldwide. Cervical squamous cell carcinoma and endocervical adenocarcinoma (CESC) are the most common histological subtypes of cervical cancer. CXC chemokines (CXCLs) within the tumor microenvironment can modulate carcinogenesis and progression. The present study aimed to explore the therapeutic and prognostic value of different CXCLs in CESC. ONCOMINE, GEPIA, cBioPortal, TRRUST, GeneMANIA, STRING and TIMER were utilized to explore the expression, mutation and function of CXCLs in CESC, as well as their correlation with pathological and survival features of CESC patients. We found that the mRNA expression levels of CXCL1/8/9/10/11/13/16/17 in CESC were upregulated compared with normal cervical tissues, whereas CXCL12 was downregulated. No significant correlation was found between the expression levels and pathological stage of CESC patients. CESC patients with high expression of CXCL1/2/3/4/5/8 were significantly associated with poor overall survival, additionally, low mRNA level of CXCL3 was associated with better disease-free survival. Besides, a high mutation rate (43%) of CXCLs in CESC was observed. Depicted by co-expression analysis, the expression of CXCL1/2/3/6/8 showed a modest to strong correlation, while that of CXCL9/10/11/13 showed a very strong correlation. Differentially expressed CXCLs primarily functioned in chemokine signaling pathway and inflammation response, such as cell chemotaxis, chemokine activity and chemokine receptor binding. We also found the association of CXCLs with the tumor-infiltration of six types of immune cells (B cells, CD8+ T cells, CD4+ T cells, macrophages, neutrophils and dendritic cells) in CESC patients. The present study elucidated that CXCLs may have the potential to be novel therapeutic targets and prognosis predictors of CESC patients.</p> </abstract>

Download Full-text

Constructing A Novel Signature Based on Immune-Related Lncrna to Improve Prognosis Prediction of Cervical Squamous Cell Carcinoma Patients

10.21203/rs.3.rs-640056/v1 ◽

2021 ◽

Author(s):

Dongchun Qin ◽

Xuefeng Lv ◽

Lu Liu ◽

Pengxiang Li ◽

Yingying Yuan ◽

...

Keyword(s):

Squamous Cell Carcinoma ◽

High Risk ◽

Cell Carcinoma ◽

Squamous Cell ◽

Risk Model ◽

Cervical Squamous Cell Carcinoma ◽

Low Risk ◽

Risk Scores ◽

Expression Levels ◽

M1 Macrophage

Abstract We downloaded gene expression data, clinical data, and somatic mutation data of cervical squamous cell carcinoma (CSCC) patients from The Cancer Genome Atlas (TCGA) and Genotype-Tissue Expression (GTEx) databases. Predictive lncRNAs were screened using univariate analysis and lasso regression, and risk score of each patient were calculated according to the expression levels of lncRNAs and regression coefficients to establish a risk model that could be a novel signature. We assessed the correlation between immune infiltration status, chemotherapeutics sensitivity, immune checkpoint proteins (ICP) and the signature. Therefore, we selected 11 immune-related lncRNAs (WWC2,AS2, STXBP5.AS1, ERICH6.AS1, USP30.AS1, LINC02073, RBAKDN, IL21R.AS1, LINC02078, DLEU1, LINC00426, BOLA3.AS1) to construct the risk model. Patients with high risk had a shorter survival time than those with low risk. Risk scores in the signature were negatively correlated with macrophage M1, macrophage M2, and T cell CD8+. The expression levels of ICP such as PD-1 were substantially higher in the low-risk group. For chemotherapeutic agents, high-risk scores were associated with higher half-inhibitory concentrations (IC50) of cisplatin. These findings suggested that the risk model can be a novel signature for predicting CSCC patients’ prognosis, and it also can be used to formulate clinical treatment plans for CSCC patients.

Download Full-text